Wyss Institute researchers have shown that gold nanoparticles can help extend the half-life of investigational cytokine interleukin 4 (IL-4), which is known to boost anti-inflammatory activity but degrades too quickly when injected alone to produce the desired effect.

It's not easy to pull off a major med-tech IPO, particularly for a diagnostics company. But Guardant Health Inc., which has staked a claim to being the leading liquid biopsy player, has priced its IPO to raise $237.5 million.